Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard E Chaisson

Showing results (41-50 of 241) with videos related to

Pageof 25
Sort By:
JAMA|July 4, 2002
Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisonersRichard E Chaisson, Joan Armstrong, John Stafford, et al.
Tropical Medicine and Infectious Disease|November 3, 2018
Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics GuidanceJustin T Denholm, Diego S Silva, Erlina Burhan, et al.
American Journal of Epidemiology|August 1, 2019
Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and DurationNicole Salazar-Austin, David W Dowdy, Richard E Chaisson, et al.
Journal of Clinical Microbiology|November 28, 2002
Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosisWalter G Park, William R Bishai, Richard E Chaisson, et al.
AIDS (London, England)|April 20, 2002
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinicGregory M Lucas, Kelly A Gebo, Richard E Chaisson, et al.
AIDS (London, England)|March 4, 2006
The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical modelDavid W Dowdy, Richard E Chaisson, Lawrence H Moulton, et al.
BMC Public Health|December 8, 2022
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic reviewWendy A Lai, Kaitlyn Brethour, Olivia D'Silva, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|August 10, 2014
Reply to "at the crossroads between early or delayed antiretroviral therapy initiation during TB/HIV coinfection"Valeria Saraceni, Betina Durovni, Antonio Guilherme Pacheco, et al.
AIDS (London, England)|November 17, 2010
Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?Alison D Grant, Katherine L Fielding, Salome Charalambous, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|January 11, 2017
RICH2 is implicated in viraemic control of HIV-1 in black South African individualsMaria Paximadis, Refilwe N Ngqobe, Richard E Chaisson, et al.
Pageof 25

Showing results (41-50 of 241) with videos related to

Sort By:
Pageof 25
JAMA|July 4, 2002
Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisonersRichard E Chaisson, Joan Armstrong, John Stafford, et al.
Tropical Medicine and Infectious Disease|November 3, 2018
Tuberculosis Elimination in the Asia-Pacific Region and the WHO Ethics GuidanceJustin T Denholm, Diego S Silva, Erlina Burhan, et al.
American Journal of Epidemiology|August 1, 2019
Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and DurationNicole Salazar-Austin, David W Dowdy, Richard E Chaisson, et al.
Journal of Clinical Microbiology|November 28, 2002
Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosisWalter G Park, William R Bishai, Richard E Chaisson, et al.
AIDS (London, England)|April 20, 2002
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinicGregory M Lucas, Kelly A Gebo, Richard E Chaisson, et al.
AIDS (London, England)|March 4, 2006
The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical modelDavid W Dowdy, Richard E Chaisson, Lawrence H Moulton, et al.
BMC Public Health|December 8, 2022
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic reviewWendy A Lai, Kaitlyn Brethour, Olivia D'Silva, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|August 10, 2014
Reply to "at the crossroads between early or delayed antiretroviral therapy initiation during TB/HIV coinfection"Valeria Saraceni, Betina Durovni, Antonio Guilherme Pacheco, et al.
AIDS (London, England)|November 17, 2010
Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?Alison D Grant, Katherine L Fielding, Salome Charalambous, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|January 11, 2017
RICH2 is implicated in viraemic control of HIV-1 in black South African individualsMaria Paximadis, Refilwe N Ngqobe, Richard E Chaisson, et al.
Pageof 25